05.11.11
WuXi PharmaTech
1Q Revenues: $93.6 million (+16%)
1Q Earnings: $18.2 million (+17%)
Comments: Laboratory Services revenues grew 12% and Manufacturing Services were up 35% for the quarter. Manufacturing growth was driven by ramp-up of large-scale commercial manufacturing and increased demand for clinical trial materials. Gross margins in manufacturing rose from 19.9% to 26.7%, while Laboratory Services' gross margins dropped from 41.4% to 39.6% due to higher labor costs, Chinese currency appreciation against the dollar, and depreciation expenses from expansion investments. Exchange rates accounted for $1.2 million of the quarter's earnings.
1Q Revenues: $93.6 million (+16%)
1Q Earnings: $18.2 million (+17%)
Comments: Laboratory Services revenues grew 12% and Manufacturing Services were up 35% for the quarter. Manufacturing growth was driven by ramp-up of large-scale commercial manufacturing and increased demand for clinical trial materials. Gross margins in manufacturing rose from 19.9% to 26.7%, while Laboratory Services' gross margins dropped from 41.4% to 39.6% due to higher labor costs, Chinese currency appreciation against the dollar, and depreciation expenses from expansion investments. Exchange rates accounted for $1.2 million of the quarter's earnings.
